FrancophonIA/ELRC3.0 huggingface dataset:
English: 10 mg/kg body weight twice daily to 20 mg/kg body weight twice daily with a maximum of 750 mg per dose, corresponding to a 0.1 mL/kg body weight twice daily to 0.2 mL/kg body weight twice daily with a maximum of 7.5 mL per dose
Maltese: 10 mg/kg ta' piż tal-ġisem darbtejn kuljum sa 20 mg/kg ta' piż tal-ġisem darbtejn kuljum b'massimu ta' 750 mg kull doża, li jikkorrispondu għal 0.1 mL/kg ta' piż tal-ġisem darbtejn kuljum sa 0.2 mL/kg ta' piż tal-ġisem darbtejn kuljum b'massimu ta' 7.5 mL kull doża.
English: CIPROXIN 100 mg/50 ml solution for infusion intravenous use
Maltese: CIPROXIN 100 mg/50 ml soluzzjoni għall-infużjoni użu għal ġol-vini
English: Mechanism of action:
Maltese: Mekkaniżmu ta' reżistenza:
English: However, this indication was not considered acceptable for the IV ciprofloxacin formulation.
Maltese: Madankollu, din l-indikazzjoni ma kinitx ikkunsidrata aċċettabbli għall-formulazzjoni ta' ciprofloxacin IV.
English: 250 mg/5 ml oral suspension oral use
Maltese: 250 mg/5 ml suspensjoni orali użu orali
English: Infections of the gastrointestinal tract and intraabdominal infections
Maltese: Infezzjonijiet ta' l-apparat gastrointestinali u infezzjonijiet intra-addominali
English: R > 1 mg/L 1 Staphylococcus spp.
Maltese: R > 1 mg/L Staphylococcus spp. - punti kritiċi għal ciprofloxacin huma konnessi ma' terapija b'doża għolja.
English: Following oral administration of single doses of 250 mg, 500 mg, and 750 mg of ciprofloxacin tablets, ciprofloxacin is absorbed rapidly and extensively, mainly from the small intestine, reaching maximum serum concentrations 1-2 hours later.
Maltese: Wara għoti orali ta' doża waħda ta' 250 mg, 500 mg, u 750 mg ta' pilloli ciprofloxacin, dan jiġi assorbit malajr u b'mod estensiv, fil-biċċa l-kbira mill-musrana ż-żgħira, u konċentrazzjonijiet massima fis-serum jintlaħqu minn siegħa sa sagħtejn wara.
English: • Pelvic inflammatory disease including cases due to Neisseria gonorrhoeae
Maltese: • Mard pelviku infjammatorju inklużi każijiet ikkaġunati minn Neisseria gonorrhoeae
English: Ciprobay XR 1000 mg modified release tablets oral use
Maltese: Ciprobay XR 1000 mg pilloli li jerħu l-mediċina b'mod modifikat użu orali
English: CIPROBAY 100 mg/50 ml solution for infusion intravenous use
Maltese: CIPROBAY 100 mg/50 ml soluzzjoni għall-infużjoni użu għal ġol-vini
English: • Inhalation anthrax (post-exposure prophylaxis and curative intent)
Maltese: • Anthrax li jittieħed man-nifs (profilassi wara l-esponiment u intenzjoni kurattiva)
English: Incompatibility appears with all infusion solutions/drugs that are physically or chemically unstable at the pH of the solution (e.g. penicillins, heparin solutions), especially in combination with solutions adjusted to an alkaline pH (pH of the ciprofloxacin infusion solutions: 3.5-4.6).
Maltese: Inkompatibilità tidher ma' kull soluzzjoni għall-infużjoni/mediċini li huma fiżikament jew kimikament mhux stabbli fil-pH tas-soluzzjoni (e.ż. penicillins, soluzzjonijiet ta' eparina), speċjalment meta jitħaltu ma' soluzzjonijiet aġġustati għall-pH alkaline (pH ta' soluzzjonijiet għall-infużjoni ta' ciprofloxacin: 3.5
English: CIPROXIN 750 mg film-coated tablets oral use
Maltese: CIPROXIN 750 mg pilloli miksija b'rita użu orali
English: 10 mg/kg body weight twice daily to 15 mg/kg body weight twice daily with a maximum of 500 mg per dose, corresponding to a 0.2 mL/kg body weight twice daily to 0.3 mL/kg body weight twice daily with a maximum of 10 mL per dose
Maltese: 10 mg/kg ta' piż tal-ġisem darbtejn kuljum sa 15 mg/kg ta' piż tal-ġisem darbtejn kuljum b'massimu ta' 500 mg kull doża, li jikkorrispondu għal 0.2 mL/kg ta' piż tal-ġisem darbtejn kuljum sa 0.3 mL/kg ta' piż tal-ġisem darbtejn kuljum b'massimu ta' 10 mL kull doża.
English: Epididymo-orchitis and pelvic inflammatory diseases may be caused by fluoroquinolone-resistant Neisseria gonorrhoeae.
Maltese: S'issa, ciprofloxacin kien il-fluoroquinolone li ntuża bliktar mod estensiv fl-adolexxenti.
English: CIPROXIN XR 1000 mg modified release tablets oral use
Maltese: CIPROXIN XR 1000 mg pilloli li jerħu l-mediċina b'mod modifikat użu orali
English: Oedema Sweating (hyperhidrosis)
Maltese: Edima Għaraq (iperidrosi)
English: 5 mL twice daily to 7.5 mL twice daily (one 5-mL measuring spoonful twice daily up to one and a half 5mL measuring spoonfuls twice daily)
Maltese: 5 mL darbtejn kuljum sa 7.5 mL darbtejn kuljum (mgħarfa waħda tal-kejl ta' 5-mL darbtejn kuljum sa mgħaref u nofs tal-kejl ta' 5-mL darbtejn kuljum)
English: Haemolytic anaemia Agranulocytosis Pancytopenia (lifethreatening) Bone marrow depression (lifethreatening)
Maltese: Anemija emolitika Agranuloċitosi Panċitopenija (ta' periklu għallħajja)
English: As Ciprofloxacin Bayer 50 mg/mL suspension contains 1.4 g sucrose per 5-mL measuring spoonful, this has to be taken into consideration in terms of daily intake.
Maltese: Minħabba li ciprofloxacin 50 mg/mL suspensjoni orali fih 1.4 g sucrose f'kull mgħarfa tal-kelj ta' 5 mL, dan għandu jiġi kkunsidrat f'termini ta' teħid ta' kuljum.
English: Aerobic Gram-positive micro-organisms Actinomyces Enteroccus faecium Listeria monocytogenes Aerobic Gram-negative micro-organisms Stenotrophomonas maltophilia Anaerobic micro-organisms Excepted as listed above Other micro-organisms Mycoplasma genitalium Ureaplasma urealitycum * Clinical efficacy has been demonstrated for susceptible isolates in approved clinical indications Resistance rate ≥ 50% in one or more EU countries ($): Natural intermediate susceptibility in the absence of acquired mechanism of resistance (1): Studies have been conducted in experimental animal infections due to inhalations of Bacillus anthracis spores; these studies reveal that antibiotics starting early after exposition avoid the occurrence of the disease if the treatment is made up to the decrease of the number of spores in the organism under the infective dose.
Maltese: Ureaplasma urealitycum * Effikaċja klinika ġiet dimostrata għal iżolati suxxettibli f'indikazzjonijiet kliniċi approvati + Rata ta' reżistenza ≥ 50 % f'wieħed jew aktar mill-pajjiżi ta' l-EU ($): Suxxettibilità intermedja naturali fin-nuqqas ta' mekkaniżmu ta' reżistenza miksub (1):
English: Indeed, ciprofloxacin is part of the drugs recommended in the European strategy targeted on treatments and prophylaxis when biological agents are used as weapons of bioterrorism.
Maltese: Ċertament, ciprofloxacin hija waħda mill-mediċini rrakkomandati fl-istrateġija Ewropea mmirata lejn trattamenti u profilassi meta mikrobi bijoloġiċi jintużaw bħala armi tal-bijoterroriżmu.
English: * Non-species-related breakpoints have been determined mainly on the basis of PK/PD data and are independent of MIC distributions of specific species.
Maltese: * Punti kritiċi li mhumiex konnessi ma' speċi ġew determinati primarjament fuq il-bażi ta' tagħrif PK/PD u huma indipendenti mid-distribuzzjonijiet ta' MIC għall-ispeċi speċifiċi.
English: 6.2 Incompatibilities [To be completed nationally]
Maltese: .2 Inkompatibilitajiet
English: - breakpoints for ciprofloxacin relate to high dose therapy.
Maltese: Staphylococcus spp. - punti kritiċi għal ciprofloxacin huma konnessi ma' terapija b'doża għolja.
English: Total duration of treatment (potentially including initial parenteral treatment with ciprofloxacin)
Maltese: Tul totali tal-kura (potenzjalment inkluż bidu ta' kura parenterali b' ciprofloxacin)
English: Effects of ciprofloxacin on other medicinal products:
Maltese: Effetti ta' ciprofloxacin fuq prodotti mediċinali oħra:
English: Ciprofloxacin reaches high concentrations in a variety of tissues such as lung (epithelial fluid, alveolar macrophages, biopsy tissue), sinuses, inflamed lesions (cantharides blister fluid), and the urogenital tract (urine, prostate, endometrium) where total concentrations exceeding those of plasma concentrations are reached.
Maltese: Ciprofloxacin jilħaq konċentrazzjonijiet għolja f'varjetà ta' tessuti bħal pulmun (fluwidu ta' l-epitelju, makrofaġi alveolari, tessut tal-bijopsija), sinuses, feriti infjammati (fluwidu finnuffata kantaridin), u l-pparat uroġenitali (awrina, prostata, endometriju) fejn jintlaħqu konċentrazzjonijiet totali li jaqabżu dawk tal-konċentrazzjonijiet fil-plażma.
English: • allergic (hypersensitive) to the active substance, to other quinolone drugs or to any of the other ingredients of Ciprofloxacin Bayer (see section 6)
Maltese: • allerġiku/a (tbati minn sensittività eċċessiva) għas-sustanza attiva , għal mediċini quinolone oħra jew sustanzi oħra ta' Ciprofloxacin Bayer (ara sezzjoni 6)
English: - a special type of reduced red blood cell count (haemolytic anaemia); a dangerous drop in a type of white blood cells (agranulocytosis ); a drop in the number of red and white blood cells and platelets (pancytopenia), which may be fatal; and bone marrow depression, which may also be fatal (see Section 2: Take special care with Ciprofloxacin Bayer) - severe allergic reactions (anaphylactic reaction or anaphylactic shock, which can be fatalserum sickness) (see Section 2: Take special care with Ciprofloxacin Bayer) - mental disturbances (psychotic reactions) (see Section 2: Take special care with Ciprofloxacin Bayer) - migraine, disturbed coordination, unsteady walk (gait disturbance), disorder of sense of smell (olfactory disorders), pressure on the brain (intracranial pressure) - visual colour distortions - inflammation of the wall of the blood vessels (vasculitis) - pancreatitis - death of liver cells (liver necrosis) very rarely leading to life-threatening liver failure - small, pin-point bleeding under the skin (petechiae); various skin eruptions or rashes (for example, the potentially fatal Stevens-Johnson syndrome or toxic epidermal necrolysis) - muscle weakness, tendon inflammation, tendon rupture - especially of the large tendon at the back of the ankle (Achilles tendon) (see Section 2: Take special care with Ciprofloxacin Bayer); worsening of the symptoms of myasthenia gravis (see Section 2: Take special care with Ciprofloxacin Bayer)
Maltese: tip speċjali ta' tnaqqis ta' l-għadd ta' ċelluli ħomor tad-demm (anemija emolitika); tnaqqis perikoluż ta' tip ta' ċelluli bojod tad-demm (agranuloċitożi); tnaqqis fin-numru ta' ċelluli ħomor u bojod tad-demm u ta' plejtlits (panċitopenija), li tista' tkun fatali; u depressjoni talmudullun ta' l-għadam li tista' tkun fatali wkoll (ara Sezzjoni 2: Oqgħod attent ħafna b'Ciprofloxacin Bayer) reazzjoni allerġika severa (reazzjoni anafilattika jew xokk anafilattiku, li tista' tkun fatalimarda tas-serum) (ara Sezzjoni 2: Oqgħod attent ħafna b'Ciprofloxacin Bayer) disturbi mentali (reazzjonijiet psikotiċi) (ara Sezzjoni 2: Oqgħod attent ħafna b'Ciprofloxacin Bayer) emigranja, disturbi fil-koordinazzjoni, mixja mhux soda (disturb fil-mixja), disturb fis-sens tax-xamm (disturbi fix-xamm), pressjoni fuq il-moħħ (pressjoni intrakranjali) disturbi fil-kuluri viżivi infjammazzjoni tal-ħajt tal-kanali tad-demm (vaskulite) pankreatite mewt ta' ċelluli tal-fwied (nekrosi tal-fwied) li rari ħafna twassal għall-insuffiċjenza tal-fwied ta' periklu għall-ħajja fsada żgħira, daqs ras ta' labra taħt il-ġilda (petekje); diversi eruzzjonijiet jew raxx fil-ġilda (eżempju, s-sindrome Stevens-Johnson li tista' tkun fatali jew nekrolisi epidermali tossika) indeboliment fil-muskoli, infjammazzjoni tat-tendon, tiċrita fit-tendon - speċjalment tattendon il-kbira wara l-għaksa (Achilles tendon) (ara Sezzjoni 2: Oqgħod attent ħafna b'Ciprofloxacin Bayer); irkadar tas-sintomi ta' myasthenia gravis (ara Sezzjoni 2:
English: Intra-abdominal infections due to Gram-negative bacteria
Maltese: Infezzjonijiet intra-addominali kkawżati minn batterja Gramnegative
English: Hepatic impairment Cholestatic icterus Hepatitis
Maltese: Indeboliment tal-fwied Ikterus kolestatiku Epatite
English: 400 mg twice daily to 400 mg three times a day
Maltese: 400 mg darbtejn kuljum to 400 mg tlitt darbiet kuljum
English: 10 mg/kg body weight twice daily to 15 mg/kg body weight twice daily with a maximum of 500 mg per dose, corresponding to a 0.1 mL/kg body weight twice daily to 0.15 mL/kg body weight twice daily with a maximum of 5 mL per dose
Maltese: 10 mg/kg ta' piż tal-ġisem darbtejn kuljum sa 15 mg/kg ta' piż tal-ġisem darbtejn kuljum b'massimu ta' 500 mg kull doża, li jikkorrispondu għal 0.1 mL/kg ta' piż tal-ġisem darbtejn kuljum sa 0.15 mL/kg ta' piż tal-ġisem darbtejn kuljum b'massimu ta' 5 mL kull doża.
English: Increase in blood alkaline phosphatase
Maltese: Żjieda fl-alkaline phosphatase fiddemm
English: The most commonly reported adverse drug reactions (ADRs) are nausea, diarrhoea, vomiting, transient increase in transaminases, rash, and injection and infusion site reactions.
Maltese: L-aktar reazzjonijiet avversi tal-mediċina (ADRs) irrapportati b'mod komuni huma tqalligħ, dijarea, rimettar, żjieda temporanja fit-transaminases, raxx u reazzjonijiet fis-sit ta' l-injezzjoni u l-infużjoni.
English: CIPROXIN 200 mg/100 ml solution for infusion intravenous use
Maltese: CIPROXIN 200 mg/100 ml soluzzjoni għall-infużjoni użu għal ġol-vini
English: o Exacerbations of chronic obstructive pulmonary disease o Broncho-pulmonary infections in cystic fibrosis or in bronchiectasis o Pneumonia
Maltese: o Taħrixiet ta' mard kroniku pulmonari okklussiv o Infezzjonijiet bronko-pulmonari f'fibrożi ċistika jew fi bronkjektażi o Pulmonite
English: 10 mg/kg body weight twice daily to 20 mg/kg body weight twice daily with a maximum of 750 mg per dose, corresponding to a 0.2 mL/kg body weight twice daily to 0.4 mL/kg body weight twice daily with a maximum of 15-mL per dose
Maltese: 10 mg/kg ta' piż tal-ġisem darbtejn kuljum sa 20 mg/kg ta' piż tal-ġisem darbtejn kuljum b'massimu ta' 750 mg kull doża, li jikkorrispondu għal 0.2 mL/kg ta' piż tal-ġisem darbtejn kuljum sa 0.4 mL/kg ta' piż tal-ġisem darbtejn kuljum b'massimu ta' 15 mL kull doża.
English: CIPROBAY 200 mg/100 ml solution for infusion intravenous use
Maltese: CIPROBAY 200 mg/100 ml soluzzjoni għall-infużjoni użu għal ġol-vini
English: Daily dose in mg and in mL
Maltese: Doża ta' kuljum f'mg u f'mL
English: 400 mg twice daily to 400 mg three times a day at least 14 days
Maltese: 400 mg darbtejn kuljum sa 400 mg tlitt darbiet kuljum ta' l-inqas 14-il ġurnata
English: Children and adolescents Indication
Maltese: Tfal u adoloxxenti Indikazzjonijiet
English: 1 measuring spoonful (approx 5.0 mL suspension) provides approx. 250 mg ciprofloxacin.
Maltese: Mgħarfa tal-kejl waħda (madwar 5.0 mL ta' suspensjoni) tipprovdi madwar 250 mg ta' ciprofloxacin.
English: The risk of tendinopathy may be increased in elderly patients or in patients concomitantly treated with corticosteroids (see section 4.8).
Maltese: Ir-riskju ta' tendinopatija jista' jiżdied f'pazjenti anzjani jew f'pazjenti kkurati fl-istess waqt b'kortikosterojdi (ara sezzjoni 4.8).
English: Bayer BV
Maltese: Bayer BV Energieweg 1
English: 100 mg/mL ORAL SUSPENSION (containing the bottle(s) for the granules and the bottle(s) for the solvent)
Maltese: TA' 100 mg/mL (fiha l-flixkun (fliexken) għall-grani u l-flixkun (fliexken) għas-solvent)
English: - the CHMP concluded that the Marketing Authorisation could be harmonised on the following indications for oral and intravenous formulations in adults:
Maltese: - is-CHMP ikkonkluda li l-Awtorizzazzjoni għat-Tqegħid fis-Suq tista' tkun armonizzata fuq lindikazzjonijiet li ġejjin għall-formulazzjonijiet orali u intravenużi fl-adulti:
English: Sucrose Load
Maltese: Kwantità ta' Sucrose
English: CIPROBAY 400 mg/200 ml solution for infusion intravenous use
Maltese: CIPROBAY 400 mg/200 ml soluzzjoni għall-infużjoni użu għal ġol-vini
English: - a special type of reduced red blood cell count (haemolytic anaemia); a dangerous drop in a type of white blood cells (agranulocytosis ) - severe allergic reaction (anaphylactic reaction, anaphylactic shock, serum sickness) which can be fatal (see Section 2: Take special care with Ciprofloxacin Bayer) - disturbed coordination, unsteady walk (gait disturbance), pressure on the brain (intracranial pressure) - visual colour distortions - various skin eruptions or rashes (e.g. the potentially fatal Stevens-Johnson syndrome or toxic epidermal necrolysis) - muscle weakness, tendon inflammation, worsening of the symptoms of myasthenia gravis (see Section 2: Take special care with Ciprofloxacin Bayer)
Maltese: tip speċjali ta' tnaqqis ta' l-għadd ta' ċelluli ħomor tad-demm (anemija emolitika); tnaqqis perikoluż ta' tip ta' ċelluli bojod tad-demm (agranuloċitożi) reazzjoni allerġika severa (reazzjoni anafilattika, xokk anafilattiku, marda tas-serum) li tista' tkun fatali (ara Sezzjoni 2: Oqgħod attent ħafna b'Ciprofloxacin Bayer) disturbi fil-koordinazzjoni, mixja mhux soda (disturb fil-mixja), pressjoni fuq il-moħħ (pressjoni intrakranjali) disturbi fil-kuluri viżivi diversi eruzzjonijiet jew raxx fil-ġilda (e.ż. s-sindrome Stevens-Johnson li tista' tkun fatali jew nekrolisi epidermali tossika) indeboliment fil-muskoli, infjammazzjoni tat-tendon, irkadar tas-sintomi ta' myasthenia gravis (ara Sezzjoni 2: Oqgħod attent ħafna b'Ciprofloxacin Bayer)
English: 50 mg/mL ORAL SUSPENSION (containing the bottle(s) for the granules and the bottle(s) for the solvent)
Maltese: TA' 50 mg/mL (fiha l-flixkun (fliexken) għall-grani u l-flixkun (fliexken) għas-solvent)
English: The proposed wording of the therapeutic indications was as follows: “Inhalation anthrax (post exposure prophylaxis and curative treatment)” for oral and IV pharmaceutical presentations.
Maltese: Anthrax li jittieħed mannifs (profilassi wara l-esponiment u trattament kurattiv)” għall-preżentazzjonijiet farmaċewtiċi orali u IV.
English: Ciprofloxacin undergoes both glomerular filtration and tubular secretion.
Maltese: Ciprofloxacin jgħaddi kemm minn filtrazzjoni glomerulari kif ukoll minn sekrezzjoni tubulari.
English: METHOD AND ROUTE(S) OF ADMINISTRATION
Maltese: Metodu ta' l-għoti
English: • to prevent infections due to the bacterium Neisseria meningitidis
Maltese: • biex jipprevjenu infezzjonijiet ikkawżati mill-batterja Neisseria meningitidis
English: Dyspepsia Flatulence
Maltese: Indeboliment talfwied
English: Ciprofloxacin Bayer 400 mg/200 mL solution for infusion is indicated for the treatment of the following infections (see sections 4.4 and 5.1).
Maltese: Ciprofloxacin Bayer 400 mg/200 mL soluzzjoni għall-infużjoni huwa ndikat għall-kura ta' linfezzjonijiet li ġejjin (ara sezzjonijiet 4.4 u 5.1).
English: Increased amylase * These events were reported during the postmarketing period and were observed predominantly among patients with further risk factors for QT prolongation (see section 4.4).
Maltese: Żjieda fl-amylase * Dawn l-avvenimenti kienu rrapportati waqt il-perijodu ta' wara t-tqegħid fis-suq u kienu osservati l-aktar f'pazjenti b'aktar fatturi ta' riskju għal titwil tal-QT (ara sezzjoni 4.4).
English: Toxic epidermal necrolysis (potentially lifethreatening)
Maltese: Nekrolisi epidermika tossika (b'potenzjal ta'
English: 400 mg three times a day
Maltese: 400 mg TID
English: • Lower respiratory tract infections due to Gram-negative bacteria
Maltese: • Infezzjonijiet tal-ġilda u tat-tessut morbidu kkaġunati minn batterji Gram-negattivi
English: Ciprofloxacin Bayer 750 mg film-coated tablets are indicated for the treatment of the following infections (see sections 4.4 and 5.1).
Maltese: Ciprofloxacin Bayer 750 mg pilloli miksija b'rita huma ndikati għall-kura ta' l-infezzjonijiet li ġejjin (ara sezzjonijiet 4.4 u 5.1).
English: Rash Pruritus Urticaria
Maltese: Mhux awtorizzat
English: CIPROXIN 400 mg/200 ml solution for infusion intravenous use
Maltese: CIPROXIN 400 mg/200 ml soluzzjoni għall-infużjoni użu għal ġol-vini
English: 10 mg/kg body weight twice daily to 20 mg/kg body weight twice daily with a maximum of 750 mg per dose.
Maltese: 10 mg/kg ta' piż tal-ġisem darbtejn kuljum sa 20 mg/kg ta' piż tal-ġisem darbtejn kuljum b'massimu ta' 750 mg kull doża.
English: Ciprofloxacin should be used with caution in patients with myasthenia gravis (see section 4.8).
Maltese: Ciprofloxacin għandu jintuża b'kawtela f'pazjenti b'myasthenia gravis (ara sezzjoni 4.8).
English: Ciproxina OD 1000 mg modified release tablets oral use
Maltese: Ciproxina OD 1000 mg pilloli li jerħu l-mediċina b'mod modifikat użu orali
English: Anaphylactic reaction Anaphylactic shock (lifethreatening) (see section
Maltese: Reazzjonijet ta' fotosensittività (ara sezzjoni
English: CIPROXIN XR 500 mg modified release tablets oral use
Maltese: CIPROXIN XR 500 mg pilloli li jerħu l-mediċina b'mod modifikat użu orali
English: CIPROBAY 250 mg film-coated tablets oral use
Maltese: CIPROBAY 250 mg pilloli miksija b'rita użu orali
English: Ciprobay XR 500 mg modified release tablets oral use
Maltese: Ciprobay XR 500 mg pilloli li jerħu l-mediċina b'mod modifikat użu orali
English: 250 mg twice daily to 500 mg twice daily
Maltese: 250 mg darbtejn kuljum sa 500 mg darbtejn kuljum2.5
English: The mean treatment duration of ciprofloxacin for MEO as reported in the meta-analysis on 13 publications, published by Gehanno (1993) was 3 months (6 months in 3 studies, 2 months in one study).
Maltese: It-tul ta' żmien medju tat-trattament b'ciprofloxacin għall-MEO kif irrappurtata fil-meta-analiżi ta' 13-il pubblikazzjoni, ippubblikati minn Gehanno (1993) kien ta' 3 xhur (6 xhur fi 3 studji, xahrejn fi studju wieħed).
English: Ciprofloxacin is a broad spectrum antibacterial agent that belongs to the fluoroquinolone family.
Maltese: Ciprofloxacin huwa mediċina antibatterika ta' spettru wiesa' li tappartjeni għall-familja ta' fluoroquinolone.
English: Ciprofloxacin Bayer 200 mg/100 mL solution for infusion is indicated for the treatment of the following infections (see sections 4.4 and 5.1).
Maltese: Ciprofloxacin Bayer 200 mg/100 mL soluzzjoni għall-infużjoni huwa ndikat għall-kura ta' linfezzjonijiet li ġejjin (ara sezzjonijiet 4.4 u 5.1).
English: Important information about some of the ingredients of Ciprofloxacin Bayer As Ciprofloxacin Bayer contains 1.4 g sucrose per 5-mL measuring spoonful, this has to be taken into consideration in terms of daily intake.
Maltese: Tagħrif importanti dwar xi wħud mis-sustanzi ta' Ciprofloxacin Bayer Peress li Ciprofloxacin Bayer fih 1.4 g ta' sucrose f' kull mgħarfa ta' kejl ta' 5mL, dan għandu jiġi kkunsidrat f' termini tad-doża ta' kuljum.
English: NAME OF THE MEDICINAL PRODUCT Ciprofloxacin Bayer and associated names (see Annex I) 750 mg film-coated tablets [See Annex I - To be completed nationally] Ciprofloxacin
Maltese: Ciprofloxacin Bayer u ismijiet assoċjati miegħu (ara Anness I) 750 mg pilloli miksija b'rita [Ara Anness I - Biex timtela mill-pajjiż partikolari] Ciprofloxacin
English: 10 mL twice daily to 15 mL twice daily (two 5-mL measuring spoonfuls twice daily up to three 5-mL measuring spoonfuls twice daily)
Maltese: 10 mL darbtejn kuljum sa 15 mL darbtejn kuljum (żewġ mgħaref tal-kejl ta' 5-mL darbtejn kuljum sa tliet mgħaref tal-kejl ta' 5-mL darbtejn kuljum)
English: 10 mL twice daily (two 5-mL measuring spoonfuls twice daily)
Maltese: 10 mL darbtejn kuljum (żewġ mgħaref tal-kejl ta' 5-mL darbtejn kuljum)
English: As a fluoroquinolone antibacterial agent, the bactericidal action of ciprofloxacin results from the inhibition of both type II topoisomerase (DNA-gyrase) and topoisomerase IV, required for bacterial DNA replication, transcription, repair and recombination.
Maltese: Bħala sustanza fluoroquinolone kontra l-batterja, l-azzjoni batteriċida ta' ciprofloxacin tirriżulta millinibizzjoni taż-żewġ topoisomerase tat-tipi II (DNA-gyrase) u ta' topoisomerase IV, li huma meħtieġa għar-replikazzjoni, transkrizzjoni, tiswija u rikombinazzjoni tad-DNA tal-batterja.
English: Gonococcal uretritis and cervicitis
Maltese: 4.1 Indikazzjonijiet terapewtiċi
English: PHARMACEUTICAL PARTICULARS 6.1 List of excipients [To be completed nationally] 6.2 Incompatibilities [To be completed nationally] 6.3 Shelf life [To be completed nationally] 6.4 Special precautions for storage [To be completed nationally] 6.5 Nature and contents of container [To be completed nationally] 6.6 Special precautions for disposal No special requirements.
Maltese: [Biex timtela mill-pajjiż partikolari] 6.2 Inkompatibilitajiet [Biex timtela mill-pajjiż partikolari] 6.3 Żmien kemm idum tajjeb il-prodott mediċinali [Biex timtela mill-pajjiż partikolari] 6.4